Skip to content
Triangle logo TriangleGet started
← Full study record

NCT02171260 · OUTCOME

Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Eribulin Mesylate

This is a Phase 1 Study of Eribulin Mesylate in Pediatric Participants With Recurrent or Refractory Solid Tumors (Excluding [Central Nervous System] CNS), Including Lymphomas · Source last updated 2019-01-15

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
hours
Interval / dispersion
Full Range
Time frame
Day 1 predose and at 10, 30 minutes, 1, 2, 4, 6, 24, 48, 72, 96 or 120 hours post-dose

Analysis population: The PAS included all participants who had sufficient PK data to derive at least one PK parameter.

Groups in this outcome

Part A1: Eribulin Mesylate 1.1 mg/m2

Participants received eribulin mesylate 1.1 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.

Part A1: Eribulin Mesylate 1.4 mg/m2

Participants received eribulin mesylate 1.4 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.

Part A1: Eribulin Mesylate 1.8 mg/m2

Participants received eribulin mesylate 1.8 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.

Part A1: Eribulin Mesylate PK Expansion

Participants received eribulin mesylate 1.4 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Part A1: Eribulin Mesylate 1.1 mg/m26
Part A1: Eribulin Mesylate 1.4 mg/m26
Part A1: Eribulin Mesylate 1.8 mg/m25
Part A1: Eribulin Mesylate PK Expansion5

Reported measurements

Source class 1
Values in hours · Interval/dispersion: Full Range
GroupValueSpreadLowerUpperComment
Part A1: Eribulin Mesylate 1.1 mg/m20.170Not reported0.120.32Not reported
Part A1: Eribulin Mesylate 1.4 mg/m20.170Not reported0.120.22Not reported
Part A1: Eribulin Mesylate 1.8 mg/m20.370Not reported0.080.50Not reported
Part A1: Eribulin Mesylate PK Expansion0.300Not reported0.170.32Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        0.12
        upper Limit
        0.32
        value
        0.170
      2. group Id
        OG001
        lower Limit
        0.12
        upper Limit
        0.22
        value
        0.170
      3. group Id
        OG002
        lower Limit
        0.08
        upper Limit
        0.50
        value
        0.370
      4. group Id
        OG003
        lower Limit
        0.17
        upper Limit
        0.32
        value
        0.300
denoms
  1. counts
    1. group Id
      OG000
      value
      6
    2. group Id
      OG001
      value
      6
    3. group Id
      OG002
      value
      5
    4. group Id
      OG003
      value
      5
    units
    Participants
dispersion Type
Full Range
groups
  1. description
    Participants received eribulin mesylate 1.1 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 4 cycles, or until PD or unacceptable toxicity or DLT's.
    id
    OG000
    title
    Part A1: Eribulin Mesylate 1.1 mg/m2
  2. description
    Participants received eribulin mesylate 1.4 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 8 cycles, or until PD or unacceptable toxicity or drug related DLT's.
    id
    OG001
    title
    Part A1: Eribulin Mesylate 1.4 mg/m2
  3. description
    Participants received eribulin mesylate 1.8 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 5 cycles, or until PD or unacceptable toxicity or drug related DLT's.
    id
    OG002
    title
    Part A1: Eribulin Mesylate 1.8 mg/m2
  4. description
    Participants received eribulin mesylate 1.4 mg/m\^2, intravenously over 2 to 5 minutes on Days 1 and 8 of each 21-day treatment cycle for up to 2 cycles, or until PD or unacceptable toxicity or drug related DLT's for evaluation of PK.
    id
    OG003
    title
    Part A1: Eribulin Mesylate PK Expansion
param Type
MEDIAN
population Description
The PAS included all participants who had sufficient PK data to derive at least one PK parameter.
reporting Status
POSTED
time Frame
Day 1 predose and at 10, 30 minutes, 1, 2, 4, 6, 24, 48, 72, 96 or 120 hours post-dose
title
Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Eribulin Mesylate
type
PRIMARY
unit Of Measure
hours

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice